Reviewing Tandem Diabetes Care (NASDAQ:TNDM) and Fielmann Group (OTCMKTS:FLMNY)

Tandem Diabetes Care (NASDAQ:TNDM) and Fielmann Group (OTCMKTS:FLMNY) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Valuation and Earnings

This table compares Tandem Diabetes Care and Fielmann Group”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.01 billion	1.53	-$204.71 million	($0.93)	-23.92
Fielmann Group	N/A	N/A	N/A	$0.37	24.80

Fielmann Group has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Fielmann Group, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tandem Diabetes Care and Fielmann Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-6.08%	-45.97%	-6.23%
Fielmann Group	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Tandem Diabetes Care and Fielmann Group, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1	11	9	1	2.45
Fielmann Group	0	0	0	0	0.00

Tandem Diabetes Care currently has a consensus price target of $28.98, indicating a potential upside of 30.22%. Given Tandem Diabetes Care’s stronger consensus rating and higher probable upside, research analysts clearly believe Tandem Diabetes Care is more favorable than Fielmann Group.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

About Fielmann Group

Fielmann Group AG provides optical and hearing aid services in Germany, Switzerland, Austria, and internationally. It manufactures and sells visual aids mainly glasses, frames, lenses, sunglasses, contact lenses, accessories, hearing aids systems and its accessories, as well as personal protective equipment. The company offers its products under the fielmann, Optika Clarus, OPTICA & AUDIOLOGIA UNIVERSITARIA, Medical optica audicion, and SVS VISION brand names. It sells its products through digital sales, retail stores, as well as Befitting, an optical e-commerce platform. The company was formerly known as Fielmann Aktiengesellschaft and changed its name to Fielmann Group AG in July 2023. Fielmann Group AG was founded in 1972 and is headquartered in Hamburg, Germany. The company is a subsidiary of Korva SE.